Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Maintenance Therapy with Daratumumab ± Pomalidomide Following Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: Results from a Phase 2 Trial
Clinical Report: Maintenance Therapy with Daratumumab ± Pomalidomide Following ASCT
Overview
This phase 2 trial evaluated daratumumab with or without pomalidomide as maintenance therapy after salvage autologous stem cell transplantation in relapsed/refractory multiple myeloma, aiming to assess progression-free survival and other clinical outcomes.
Background
Salvage autologous stem cell transplantation (ASCT) remains a significant treatment option for relapsed/refractory multiple myeloma (RRMM). Maintenance therapy post-ASCT has been shown to improve progression-free survival, yet evidence for maintenance after salvage ASCT is limited. This study investigates the role of daratumumab, a monoclonal antibody, in this context.
Data Highlights
Key findings from the trial include the study's premature termination due to slow patient accrual and the primary endpoint of progression-free survival.
Key Findings
The study was conducted at The University of Texas MD Anderson Cancer Center.
Eligibility included adults with RRMM who had undergone ASCT 60–180 days prior.
Patients received daratumumab weekly for the first eight weeks, followed by biweekly and then monthly doses.
The study aimed to enroll 56 patients but ended prematurely due to slow accrual.
Progression-free survival was the primary endpoint, with secondary endpoints including overall survival and measurable residual disease negativity.
Clinical Implications
The findings from this trial may inform future studies on maintenance therapy options for patients with RRMM following salvage ASCT. The role of daratumumab in this setting could be further explored in larger, more definitive trials.
Conclusion
This phase 2 trial investigates maintenance therapy options for RRMM following salvage ASCT, particularly the use of daratumumab.
by Oren Pasvolsky, Bruno Almeida Costa, Yosra M. Aljawai, Krina K. Patel, Qaiser Bashir, Dawen Sui, Samer A. Srour, Mark R. Tanner, Uday R. Popat, Neeraj Y. Saini, Chitra Hosing, Jeremy L. Ramdial, Hans C. Lee, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Melody Becnel, Guilin Tang, Robert Z. Orlowski, Richard E. Champlin, Yago Nieto, Elizabeth J. Shpall, Muzaffar H. Qazilbash
IBTV speaks with industry leaders at ASGCT 2026 about the technologies, processes, and manufacturing strategies helping advanced therapies progress toward commercial scale
